开发用于管理散发性或遗传性结直肠癌风险患者的药物的临床终点。
Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.
机构信息
Department of Internal Medicine, The University of Arizona Medical Center, PO Box 245040, 1501 N Campbell Avenue, Tucson, AZ 85724, USA.
出版信息
Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):507-17. doi: 10.1586/egh.12.23.
Abstract
To reduce the morbidity and mortality from colorectal cancer (CRC), current clinical practice focuses on screening for early detection and polypectomy as a form of secondary prevention, complemented with surgical interventions when appropriate. No pharmaceutical agent is currently approved for use in clinical practice for the management of patients at risk for CRC. This article will review earlier attempts to develop pharmaceuticals for use in managing patients with a sporadic or genetic risk of CRC. It will also discuss therapeutic end points under evaluation in current efforts to develop drugs for treating CRC risk factors.
摘要
为了降低结直肠癌（CRC）的发病率和死亡率，目前的临床实践侧重于筛查以早期发现和息肉切除术作为二级预防手段，并在适当情况下辅以手术干预。目前尚无药物制剂被批准用于 CRC 风险患者的临床管理。本文将回顾早期开发用于管理散发性或遗传性 CRC 风险患者的药物制剂的尝试。它还将讨论目前开发治疗 CRC 风险因素药物的努力中正在评估的治疗终点。
相似文献
1
Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.开发用于管理散发性或遗传性结直肠癌风险患者的药物的临床终点。
Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):507-17. doi: 10.1586/egh.12.23.
2
Chemoprevention of colorectal cancer: systematic review and economic evaluation.结直肠癌的化学预防：系统评价和经济评估。
Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320.
3
Is there any role for prevention strategies for colorectal cancer other than population-based screening?除了基于人群的筛查外，结直肠癌的预防策略还有其他作用吗？
Bratisl Lek Listy. 2004;105(5-6):215-24.
4
Management of high-risk colonoscopy patients.高危结肠镜检查患者的管理
Gastrointest Endosc Clin N Am. 2010 Oct;20(4):629-40. doi: 10.1016/j.giec.2010.07.015.
5
Chemoprevention with special reference to inherited colorectal cancer.化学预防，特别涉及遗传性结直肠癌
Fam Cancer. 2008;7(1):59-64. doi: 10.1007/s10689-007-9158-4. Epub 2007 Aug 7.
6
[Colorectal cancer chemoprevention].[结直肠癌化学预防]
Pol Merkur Lekarski. 2007 Jul;23(133):70-3.
7
Genetic predisposition to colorectal cancer: Implications for treatment and prevention.结直肠癌的遗传易感性：对治疗和预防的意义。
Semin Oncol. 2016 Oct;43(5):536-542. doi: 10.1053/j.seminoncol.2016.08.002. Epub 2016 Sep 1.
8
Can the identification of high risk groups increase the effectiveness of colon cancer screening programmes?识别高危人群能否提高结肠癌筛查项目的有效性？
Z Gastroenterol. 2008 Apr;46 Suppl 1:S41-2. doi: 10.1055/s-2007-963483.
9
Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.依氟鸟氨酸（CPP-1X）/舒林酸联合疗法与单药疗法治疗家族性腺瘤性息肉病（FAP）患者的疗效和安全性：一项随机、双盲、III期试验的设计与原理
BMC Gastroenterol. 2016 Aug 2;16(1):87. doi: 10.1186/s12876-016-0494-4.
10
Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines.遗传性结直肠癌综合征：美国临床肿瘤学会临床实践指南对家族性结直肠癌风险的认可：欧洲肿瘤内科学会临床实践指南。
J Clin Oncol. 2015 Jan 10;33(2):209-17. doi: 10.1200/JCO.2014.58.1322. Epub 2014 Dec 1.
引用本文的文献
1
Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse Model.在经氧化偶氮甲烷处理的小鼠模型中，间歇性给予舒林酸可有效预防结直肠癌。
Cancer Prev Res (Phila). 2017 Aug;10(8):459-466. doi: 10.1158/1940-6207.CAPR-17-0038. Epub 2017 Jun 13.
2
New trends in molecular and cellular biomarker discovery for colorectal cancer.结直肠癌分子和细胞生物标志物发现的新趋势
World J Gastroenterol. 2016 Jul 7;22(25):5678-93. doi: 10.3748/wjg.v22.i25.5678.
本文引用的文献
1
DFMO: targeted risk reduction therapy for colorectal neoplasia.DFMO：结直肠肿瘤的靶向风险降低治疗。
Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):495-506. doi: 10.1016/j.bpg.2011.09.007.
2
Aspirin in the chemoprevention of colorectal neoplasia: an overview.阿司匹林在结直肠肿瘤化学预防中的应用：概述。
Cancer Prev Res (Phila). 2012 Feb;5(2):164-78. doi: 10.1158/1940-6207.CAPR-11-0391. Epub 2011 Nov 14.
3
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.遗传性结直肠癌携带者中阿司匹林对癌症风险的长期影响：来自 CAPP2 随机对照试验的分析。
Lancet. 2011 Dec 17;378(9809):2081-7. doi: 10.1016/S0140-6736(11)61049-0. Epub 2011 Oct 27.
4
Nuclear factor kappa B (NF-κB): a novel cause for diabetes, coronary artery disease and cancer initiation and promotion?核因子 kappa B（NF-κB）：糖尿病、冠心病和癌症发生与促进的新病因？
Med Hypotheses. 2012 Jan;78(1):29-32. doi: 10.1016/j.mehy.2011.09.034. Epub 2011 Oct 19.
5
Therapeutic prevention of colorectal carcinogenesis.结直肠癌发生的治疗性预防
J Carcinog. 2011;10:13. doi: 10.4103/1477-3163.79682. Epub 2011 Apr 16.
6
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.癌症统计数据，2011 年：消除社会经济和种族差异对癌症过早死亡的影响。
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. doi: 10.3322/caac.20121. Epub 2011 Jun 17.
7
Of timing and surrogates: a way forward for cancer chemoprevention.关于时机和替代终点：癌症化学预防的前进之路。
Clin Cancer Res. 2011 Jun 1;17(11):3509-11. doi: 10.1158/1078-0432.CCR-11-0643. Epub 2011 Apr 15.
8
Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.随机双盲试验：舒林酸与依托度酸根除结肠异形隐窝病灶及预防散发性结直肠息肉
Clin Cancer Res. 2011 Jun 1;17(11):3803-11. doi: 10.1158/1078-0432.CCR-10-2395. Epub 2011 Mar 8.
9
Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic.癌症风险降低（化学预防）药物的监管批准：将我们所学到的知识应用于临床。
Cancer Prev Res (Phila). 2011 Mar;4(3):311-23. doi: 10.1158/1940-6207.CAPR-09-0014.
10
Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.鸟氨酸脱羧酶-1 多态性、依氟鸟氨酸和舒林酸的化学预防以及结直肠腺瘤患者的结局。
J Natl Cancer Inst. 2010 Oct 6;102(19):1513-6. doi: 10.1093/jnci/djq325. Epub 2010 Aug 26.
Zotero 插件